[ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease].

Abstract

Correlation association between an ApoE4 genotype in patients with mild-moderate Alzheimer's disease and efficacy of neurotrophic (cerebrolysin) and cholinergic (exelon) therapy was studied in the groups of patients formed using case-control method. A 4-month treatment has shown that both types of therapy had a significant clinical effect, however clinical effect proved to be more higher and stable in patients treated with cerebrolysin. A number of responders in the cerebrolysin group was 1.7-fold higher comparing to that in the exelon group. Patients with the ApoE4(+) genotype did not differ in response to either drug but in those with genotype ApoE4(-) the number of responders was 3-fold higher in the group treated with cerebrolysin compared to the group given exelon. A follow-up estimation of cognitive impairment in ApoE4(-) patients revealed that long-term clinical effect of cerebrolysin treatment was 6.5 times higher than that of exelon.

• Authors: S I Gavrilova, I V Kolykhalov, G I Korovaĭtseva, G A Zharikov, Ia B Kalyn, N D Selezneva
• Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (Zh Nevrol Psikhiatr Im S S Korsakova) Vol. 105 Issue 4 Pg. 27-34 ( 2005) ISSN: 1997-7298 [Print] Russia (Federation)
• PMID: 15880838 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Amino Acids
• Apolipoproteins E
• Cholinesterase Inhibitors
• Nerve Growth Factors
• Nootropic Agents
• Phenylcarbamates
• cerebrolysin
• Rivastigmine

Topics

• Activities of Daily Living
• Aged
• Aged, 80 and over
• Alzheimer Disease (diagnosis, drug therapy, genetics)
• Amino Acids (therapeutic use)
• Apolipoproteins E (genetics)
• Cholinesterase Inhibitors (therapeutic use)
• Female
• Follow-Up Studies
• Genotype
• Humans
• Male
• Middle Aged
• Nerve Growth Factors (metabolism)
• Neuropsychological Tests
• Nootropic Agents (therapeutic use)
• Phenylcarbamates (therapeutic use)
• Rivastigmine